Casey, Dan and I met with Marty Tenenbaum founder of CollabRx and Tony Ley its CEO last week to get up to speed on their strategy for providing tools to patient groups and virtual biotechs to accelerate the development of treatments for diseases that don't attract major pharmaceutical company research funding. Today's WSJ details Marty's personal cancer stories and the goals of CollabRx. We discussed several ways that NIO and the broader neurotech research community could benefit from CollabRx. More on that as things get solidified. In the meantime, I highly recommend getting up to speed on the company. If anyone can instigate a sea change in this arena, it's Marty and the amazing ecosystem of relationships he wields.
Thanks for signing in,
.
Now you can comment. (sign out)
(If you haven't left a comment here before, you may need to be approved by the site owner before your comment will appear. Until then, it won't appear on the entry. Thanks for waiting.)